Nitrazepam Dawa

Nitrazepam, the active ingredient in Nitrazepam Dawa, is a benzodiazepine presented as an oral tablet for oral use. It is prescribed to adult patients for the management of insomnia, anxiety disorders, and certain seizure disorders, acting as a hypnotic and anxiolytic agent.

GNH USA supplies Nitrazepam Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Nitrazepam belongs to the benzodiazepine class and is used to treat central nervous system disorders that require sedation or seizure control. - Insomnia: helps patients fall asleep faster and maintain sleep throughout the night. - Anxiety disorders: reduces excessive worry and tension in individuals with generalized anxiety. - Seizure disorders: provides adjunctive control of certain types of epileptic seizures.

Nitrazepam may cause a range of adverse reactions, from mild to severe, depending on patient factors and concomitant therapies.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: reduced motor control and balance. - Memory impairment: difficulty recalling recent events. - Headache: mild to moderate head pain. - Fatigue: persistent lack of energy.

Serious or Rare Side Effects: - Depression or suicidal thoughts: mood changes requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or difficulty breathing. - Respiratory depression: slowed breathing, especially with other depressants. - Paradoxical agitation: increased anxiety or aggression. - Dependence or withdrawal syndrome: physical reliance after prolonged use. - Hepatic dysfunction: abnormal liver enzyme elevations.

Nitrazepam requires careful use and monitoring to minimize risks. - Assess renal function: adjust therapy in patients with severe renal impairment. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal. - Use caution in elderly: increased sensitivity to sedation and falls. - Pregnancy: category D, prescribe only when benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nitrazepam can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Other CNS depressants (e.g., opioids, barbiturates): risk of profound sedation and respiratory depression. - Alcohol: additive central nervous system depression. - Antifungal azoles such as ketoconazole: may increase nitrazepam plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise nitrazepam levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Antidepressants (e.g., SSRIs, SNRIs): can enhance sedative properties.